Invokana Linked to Acute Pancreatitis

Written by admin


Invokana associated with several life threatening complications include Renal Failure or acute Kidney Failure, Heart Attack, Urinary Tract Infections, Bone Fractures and Ketoacidosis (DKA). The new investigation performed by the U.S. Food and Drug Administration (FDA) resulted with a severe risk associated with Invokana. According the FDA report SGLT2 inhibitor Type 2 diabetes medications are associated with Acute Pancreatitis. Invokana (canagliflozin) is one of several “new generation” type 2 diabetes drugs known as SGLT2 inhibitors approved on March 29, 2013 by U.S Food and Drugs Administration. The drug inhibits normal kidney function to allow patients to pass excess blood glucose through urination.  It is manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. Janssen also markets Invokamet, a combination of canagliflozin and metformin. According to the agency they have revised the warnings in the drug labels to include information about the severe risk cause by the medicine and added recommendations to minimize this risk.

Acute Pancreatitis is a condition in which inflammation of the pancreas develops quickly. There are some sign and symptoms of the disease. The main symptom is tummy (abdominal) pain, most often located in the upper abdomen and may radiate directly through to the back. The patient may feel nausea and vomiting, sometimes with anorexia. The most common causes of acute pancreatitis are gallstones and drinking a lot of alcohol. The patients with severe Acute Pancreatitis are very critical to recognize within the time and about 10 percent of Acute Pancreatitis cases are fatal. Intensive cares treatment is provided to the patient who develops severe acute pancreatitis. Surgical intervention (open or minimally invasive) is indicated in selected cases. The Food and Drug Administration previously issued safety warnings about the risk of acute pancreatitis in the DPP-4 class of Type 2 diabetes drugs and is now investigating adverse event reports for SGLT2 inhibitors.

Sodium glucose transporter 2 (SGLT2) inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. SGLT2 inhibitors are attractive agents in managing diabetes cause of their additional beneficial effects on blood pressure and lipids. SGLT2 inhibitors work by preventing the kidneys from reabsorbing glucose back into the blood. The drugs belong to the SGLT2 inhibitors class are Farxiga (dapagliflozin), Xigduo XR (dapagliflozin and metformin extended-release), Invokamet (canagliflozin and metformin), Jardiance (empagliflozin), Glyxambi (empagliflozin and linagliptin). According to the studies FDA determines that these drugs are associated with an increased risk for acute pancreatitis. From 2015 and 2016 many medical journal articles explain the cases of acute pancreatitis in patients who took Invokana.

Plaintiffs from all over the nation filed lawsuits against the manufacturers alleging that Invokana is associated with several adverse events and the manufacturers have failed to warn patients and doctors about the life threatening risk associated with the diabetic medicine. If you or your loved ones experienced acute pancreatitis and Kidney Failure or suffering from any of the symptoms like lower limb amputation, Ketoacidosis (DKA) or other adverse effects while taking Invokana medication, now is the time to seek legal advice. Contact for free evaluation of the case. We have years of experience, knowledgeable and skillful lawyers. All cases are pursued on a contingency fee basis there are never any out-of-pocket costs to hire our attorneys unless we win the case for you.



About the author


Leave a Comment